9:16 AM ET
8-K
Nasdaq/NYSE Compliance Notice
Liminatus Pharma Nasdaq/NYSE Compliance Notice
Liminatus Pharma has regained compliance with Nasdaq's minimum bid price requirement after its common stock maintained a closing bid price above $1.00 for 13 consecutive trading days. The company previously effected a 1-for-50 reverse stock split on August 20, 2026, to address the deficiency. Nasdaq has officially closed the matter, and the company remains listed on The Nasdaq Capital Market.
- Counterparty
- Nasdaq